How a single inversion of configuration leads to a reversal of the binding mode: Proposal of a novel arrangement of CCK2 ligands in their receptor, and contribution to the development of peptidomimetic or non-peptide CCK2 ligands

European Journal of Medicinal Chemistry

Volumn 38, Issue 7-8, 2003, Pages 671-686

  Bellier, Bruno ^a,c   Garbay, Christiane ^a,b  

^a Laboratoire de Pharmacochimie   (France)

^b CNRS   (France)

^c CENTRE D ETUDES DU BOUCHET   (France)

Author keywords

Binding mode; CCK2; Cholecystokinin; Peptidomimetics

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; PEPTIDE; RB 213; RB 400; TRYPTOPHAN; UNCLASSIFIED DRUG; [2 [(2 HYDROXYCYCLOHEXYL)AMINO] 1 (1H INDOL 3 YLMETHYL) 1 METHYL 2 OXOETHYL]CARBAMIC ACID 2 ADAMANTYL ESTER;

AMINO TERMINAL SEQUENCE; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0043158863     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(03)00112-0     Document Type: Review

References (58)

1. The word "peptoid" will frequently be used in this text in an inconvenient way, to be understood as "peptidomimetic". To support this misuse, we may stress that this family of CCK ligands has been named the "dipeptoid" family for more than ten years and is well-known in the field... but, in any case, the word "dipeptoid" was used between commas to make this misuse clearer to the reader.
2. Rehfeld J.F. J. Biol. Chem. 253:1978;4022-4030.
3. Makovec F., D'Amato M. Drug Discov. Today. 2:1997;283-293.
4. Crawley J., Corwin R. Peptides. 15:1994;731-755.
5. Daugé V., Léna I. Neurosci. Biobehav. Rev. 22:(6):1998;815-825.
6. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M., Roques B.P. Pharmacol. Rev. 51:1999;745-781.
7. Noble F., Roques B.P. Prog. Neurobiol. 58:(4):1999;349-379.
8. Innis R.B., Snyder S.H. Proc. Natl. Acad. Sci. USA. 77:1980;6917-6921.
9. Charpentier B., Pélaprat D., Durieux C., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Proc. Natl. Acad. Sci. USA. 85:1988;1968-1972.
10. Charpentier B., Durieux C., Pélaprat D., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Peptides. 9:1988;835-841.
11. B. Bellier, Ph.D. Dissertation, Université Paris V, 2000.
12. Blommaert A.G., Dhotel H., Ducos B., Durieux C., Goudreau N., Bado A., Garbay C., Roques B.P. J. Med. Chem. 40:1997;647-658.
13. Rolland M., Rodriguez M., Lignon M.F., Galas M.C., Laur J., Aumelas A., Martinez J. Intl. J. Pept. Prot. Res. 38:1991;181-192.
14. Shiosaki K., Lin C.W., Kopecka H., Craig R., Wagenaar F.L., Bianchi B., Miller T., Witte D., Nadzan A.M. J. Med. Chem. 33:1990;2950-2952.
15. Horwell D.C. Neuropeptides. 19:(Suppl):1991;57-64.
16. Horwell D.C., Beeby A., Clark C.R., Hughes J. J. Med. Chem. 30:1987;729-732.
17. Horwell D.C., Hughes J., Hunter J.C., Pritchard M.C., Richardson R.S., Roberts E., Woodruff G.N. J. Med. Chem. 34:1991;404-414.
18. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., Woodruff G.N. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
19. Blommaert A.G.S., Weng J.H., Dorville A., McCort I., Ducos B., Durieux C., Roques B.P. J. Med. Chem. 36:1993;2868-2877.
20. Trivedi B.K., Padia J.K., Holmes A., Rose S., Wright D.S., Hinton J.P., Pritchard M.C., Eden J.M., Kneen C., Webdale L., Suman-Chauhan N., Boden P., Singh L., Field M.J., Hill D. J. Med. Chem. 41:1998;38-45.
21. Horwell D., Pritchard M., Raphy J., Ratcliffe G. Immunopharmacology. 33:1996;68-72.
22. Suman-Chauhan N., Meecham K.G., Webdale L., Hunter J.C., Pritchard M.C., Woodruff G.N., Hill D.R. Regul. Pept. 65:1996;37-43.
23. Silvente-Poirot S., Escrieut C., Galès C., Fehrentz J.A., Escherich A., Wank S.A., Martinez J., Moroder L., Maigret B., Bouisson M., Vaysse N., Fourmy D. J. Biol. Chem. 274:1999;23191-23197.
24. Tilley J.W., Danho W., Madison V., Fry D., Swistok J., Makofske R., Michalewsky J., Schwartz A., Weatherford S., Triscari J. J. Med. Chem. 35:1992;4249-4252.
25. P.J. Corringer, Ph.D. Dissertation, Université Paris V, 1992.
26. Drysdale M.J., Pritchard M.C., Horwell D.C. J. Med. Chem. 35:1992;2573-2581.
27. Boden P.R., Eden J.M., Higginbottom M., Hill D.R., Horwell D.C., Hunter J.C., Martin K., Pritchard M.C., Richardson R.S., Roberts E. Eur. J. Med. Chem. 28:1993;47-61.
28. Bischoff L., David C., Roques B.P., Fournié-Zaluski M.C. J. Org. Chem. 64:1999;1420-1423.
29. Corringer P.J., Weng J.H., Ducos B., Durieux C., Boudeau P., Bohme A., Roques B.P. J. Med. Chem. 36:1993;166-172.
30. Eden J.M., Boden P.R., Hill D.R., Horwell D.C., Hunter J.C., Martin K., Pritchard M.C., Rahman S.S., Richardson R.S., Roberts E. Eur. J. Med. Chem. 28:1993;37-45.
31. Goudreau N., Weng J.H., Roques B.P. Biopolymers. 34:1994;155-169.
32. Bellier B., Million M.-E., Danascimento S., Meudal H., Kellou S., Maigret B., Garbay C. J. Med. Chem. 43:2000;3614-3623.
33. Million M.-E., Léna I., Danascimento S., Noble F., Daugé V., Garbay C., Roques B.P. Lett. Pept. Sci. 4:1997;407-410.
34. To make easier the relation between the number of a compound and its structure, and since new compounds with very different chemical structures have been prepared, we decided to number with the same "root number" (4 to 10) compounds starting from a common precursor. Only compounds discussed in the text were numbered. When compounds could be characterised by a cis or trans orientation of essential substituents, they were differentiated by a logical additional lettering (c for cis, i.e. 6c, t for trans, i.e. 6t). When this was not possible, additional lettering was done logically, following the synthetic pathway (8, then 8a, 8b,...). When two stereoisomers were isolated from a parent cis or trans racemate, a second letter was added (7ca, 7cb from 7c) to keep the c/t indication. Lastly, conversion of a Trp-containing compound into its α-Me-Trp analogue led to introduction of an additional 'm' lettering (9mt).
35. Bellier B., McCort-Tranchepain I., Ducos B., Danascimento S., Meudal H., Noble F., Garbay C., Roques B.P. J. Med. Chem. 40:1997;3947-3956.
36. Detailed experimental data is available as supplementary material.
37. 2H).
38. Oldenziel O.H., Wildeman J., Van Leusen A.M. Org. Synth. 57:1977;8-10.
39. Satoh T., Suzuki S. Tetrahedron Lett. 52:1969;4555-4558.
40. Bodanszky M., Martinez J., Walker M., Gardner J.D., Mutt V. J. Med. Chem. 23:1980;82-85.
41. Pierson M.E., Comstock J.M., Simmons R.D., Kaiser F., Julien R., Zongrone J., Rosamond J.D. J. Med. Chem. 40:1997;4302-4307.
42. Ruiz-Gayo M., Daugé V., Menant I., Bégué D., Gacel G., Roques B.P. Peptides. 6:1985;415-420.
43. Durieux C., Pélaprat D., Charpentier B., Morgat J.L., Roques B.P. Neuropeptides. 12:1986;141-148.
44. Higginbottom M., Kneen C., Ratcliffe G.S. J. Med. Chem. 35:1992;1572-1577.
45. Weng J.H., Blommaert A.G., Moizo L., Bado A., Ducos B., Böhme A., Garbay C., Roques B.P. Bioorg. Med. Chem. 4:1996;563-573.
46. Knight M., Barone P., Tamminga C.A., Steardo L., Chase T.N. Peptides. 6:1985;631-634.
47. Gregory R.A., Tracy H.J. Gut. 5:1964;103-117.
48. Fujimoto M., Igano K., Watanabe K., Irie I., Inouye K., Okabayashi O. Biochem. Pharmacol. 34:1985;1103-1107.
49. M. Amblard, M. Rodriguez, M.C. Galas, M.F. Lignon, N. Bernad, J. Martinez, Proceedings of the 12th American Peptide Symposium (1991) 474-475.
50. Härhammer R., Schäfer U., Henklein P., Ott T., Repke H. Eur. J. Pharmacol. 209:1991;263-266.
51. Horwell D.C. Bioorg. Med. Chem. 4:1996;1573-1576.
52. McElroy A.B., Clegg S.P., Deal M.J., Ewan G.B., Hagan R.M., Ireland S.J., Jordan C.C., Poerter B., Ross B.C., Ward P., Whittington A.P. J. Med. Chem. 35:1992;2582-2591.
53. Boyle S., Guard S., Higginbottom M., Horwell D.C., Howson W., McKnight A.T., Marin K., Pritchard M.C., O'Toole J., Raphy J. Bioorg. Med. Chem. 2:1994;357-370.
54. Hughes J., Dockray G.J., Hill D., Garcia L., Pritchard M.C., Forster E., Toescu E., Woodruff G., Horwell D.C. Regul. Pept. 65:1996;15-21.
55. see for instance Davey A.E., Horwell D.C., Bioorg. Med. Chem. 1 (1993) 45-58 [published erratum appears in Bioorg. Med. Chem. 1 (1993) 235].
56. Aquino C.J., Armour D.R., Berman J.M., Birkemo L.S., Carr R.A., Croom D.K., Dezube M., Dougherty R.W. Jr., Ervin G.N., Grizzle M.K., Head J.E., Hirst G.C., James M.K., Johnson M.F., Miller L.J., Queen K.L., Rimele T.J., Smith D.N., Sugg E.E. J. Med. Chem. 39:1996;562-569.
57. Magous R., Martinez J., Lignon M.F., Bali J.P. Regul. Pept. 5:1983;327-332.
58. Pan G.Z., Martinez J., Bodanszky M., Jensen R.T., Gardner J.D. Biochim. Biophys. Acta. 678:1981;352-357.